Tuberculosis diagnosed in a rural setting in angola. accuracy of follow-up sputum smears to predict outcome

Pathogens and Global Health

Volumn 107, Issue 1, 2013, Pages 5-10

  López, Teresa ^a   Moreno, Milagros ^a   Salvador, Fernando ^b   Zacarías, Adriano ^a   de Carvalho, Rosa ^a   Tomás, Estevao ^a   Estevao, Gabriel ^a   Eugenio, Arlette Nindia ^a   Burgos, Joaquin ^a   Sulleiro, Elena ^b   Molina, Israel ^b   Falcó, Vicenç ^b  

^a Hospital Nossa Senhora da Paz de Cubal   (Angola)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Multidrug resistant tuberculosis; Predictors of treatment failure; Tuberculosis; Tuberculosis in resource limited settings

Indexed keywords

ETHAMBUTOL PLUS ISONIAZID; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ANGOLA; ARTICLE; CHILD; DEATH; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRESCHOOL CHILD; QUALITY CONTROL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SPUTUM SMEAR; TREATMENT FAILURE; TREATMENT RESPONSE; TUBERCULOSIS;

ADOLESCENT; ADULT; ANGOLA; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RURAL POPULATION; SPUTUM; TREATMENT FAILURE; TUBERCULOSIS; YOUNG ADULT;

EID: 84873528586     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047773212Y.0000000066     Document Type: Article

References (22)

1. Lawn SD, Zumla AI. Tuberculosis. Lancet. 2011;378:57-72.
2. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. WHO/CDS/TB/ 2003.313. Geneva: World Health Organization; 2003.
3. Wallis RS, Doherty TM, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2009;9:162-72.
4. Wilkinson D, Bechan S, Connolly C, Standing E, Short GM. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? Int J Tuberc Lung Dis. 1998;2:52-5.
5. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th ed. WHO/HTM/TB/ 2009.420. Geneva: World Health Organization; 2010.
6. World Health Organization UNAIDS (2007) Guidance on provider-initiated HIV testing and counselling in health facilities. Geneva, World Health Organization.
7. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, et al. Speaking the same language: treatment outcome definitions for multidrug resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640-5.
8. Horne DJ, Royce SE, Gooze L, Narita M, Hopewell PC, Nahid P, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10:387-94.
9. Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ. 2004;329:168-9.
10. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med. 2006;144:650-9.
11. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. WHO/HTM/TB/2008.402. Geneva: World Health Organization; 2008.
12. Mitchinson DA. Assesment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis. 1993;147:1062-3.
13. Long NH, Johansson E, Lönnroth K, Eriksson B, Winkvist A, Diwan VK. Longer delays in tuberculosis diagnosis among women in Vietnam. Int J Tuberc Lung Dis. 1999;3:388-93.
14. Hudelson P. Gender differentials in tuberculosis: the role of socio-economic and cultural factors. Tuber Lung Dis. 1996;77:391-400.
15. Cheng G, Tolhurst R, Li RZ, Meng QY, Tang S. Factors affecting delays in TB diagnosis in rural China: a case study in four counties in Shandong Province. Trans R Soc Trop Med Hyg. 2005;99:355-62.
16. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001;5:887-93.
17. Yoshiyama T, Yanai H, Rhiengtong D, Palittapongarnpim P, Nampaisan O, Supawitkul S, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis. 2004;8:31-8.
18. Faustini A, Hall AJ, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61:158-63.
19. Zignol M, Wright A, Jaramillo E, Nunn P, Raviglione MC. Patients with previously treated Tuberculosis no longer neglected. Clin Infect Dis. 2007;44:61-4.
20. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with monoresistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6:e1000150.
21. Oxlade O, Schwartzman K, Pai M, Heymann J, Benedetti A, Royce S, et al. Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. Eur Respir J. 2010;36:870-7.
22. Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516-28.